Telix Pharmaceuticals (TLX) H1 2024 earnings summary

Executive summary

• Achieved strong commercial and operational progress in H1 2024, with revenue growing 65% year-over-year to $364.0M, driven by Illuccix® U.S. sales and global expansion across prostate, kidney, and brain cancer programs.

• Positive data from prostate therapy studies and expansion of the Prostact global phase III trial, including US sites.

• Completed strategic acquisitions of ARTMS, IsoTherapeutics, and QSAM Biosciences, enhancing manufacturing, supply chain, and product pipeline.

• Raised AUD 650 million ($650M) in convertible bonds, significantly strengthening the balance sheet and providing capacity for accelerated clinical development.

• Net profit after tax was $29.7M, a $44.0M improvement from a $14.3M loss in H1 2023.

Financial highlights

• Revenue grew 65% year-over-year to $364.0M, driven primarily by Illuccix® sales in the U.S.

• Gross margin improved to 66% from 63% in H1 2023.

• Adjusted EBITDA increased 66% to $57.5M (H1 2023: $34.7M).

• Operating profit from the commercial business rose 86% to AUD 175 million, representing 49% of sales.

• Operating cash inflow rose to $39.1M (H1 2023: $13.3M); cash balance at 30 June 2024 was $118.8M.

Outlook and guidance

• Full-year revenue guidance set at AUD 745–776 million (US$490M–US$510M), a 48–54% increase on 2023.

• Anticipates further revenue growth from US Illuccix® market, geographic expansion, and new product launches in kidney and brain cancer.

• Focused on advancing mid-stage pipeline assets in renal and brain cancer toward pivotal trials.

• Expects to submit Zircaix for European approval early next year, with manufacturing readiness aligned.

• EU and UK regulatory decisions for Illuccix® expected in H2 2024; Brazil approval anticipated in Q3 2024.